Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Precursor dendritic cell proliferation in multiple myeloma : a precursor to acute myeloid leukemia
Avtorji:ID Reberšek, Katarina (Avtor)
ID Anžej Doma, Saša (Avtor)
ID Škerget, Matevž (Avtor)
ID Podgornik, Helena (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,48 MB)
MD5: 0B03F64A59448364DFC6D26F0154872A
 
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2038-8330/18/1/3
 
Jezik:Angleški jezik
Tipologija:1.03 - Drugi znanstveni članki
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Background: Dendritic cells (DCs) are heterogeneous antigen-presenting cells that bridge innate and adaptive immunity. Recent classifications of hematolymphoid neoplasms highlight the complex origins of DC-related neoplasms. DCs have also been associated with the progression of multiple myeloma (MM). This report presents the case of a patient with MM in whom bone marrow analysis revealed an unusual additional clonal population of immature cells, in addition to plasmacytoid DCs, that later evolved into plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia (pDC-AML). Methods: The bone marrow of a 69-year-old man with neutropenia and thrombocytopenia was examined by morphology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). Serial assessments were performed before and during treatment with bortezomib and dexamethasone for MM, and later with daunorubicin/cytarabine for AML. Results: Initial bone marrow analysis revealed coexisting clonal plasma cells with t(11;14) and a population of CD34+/CD123+/CD45RA+ cells lacking lineage markers, in addition to pDCs, suggestive of precursor DCs rather than acute undifferentiated leukemia. Cytogenetic analysis identified a small clone with isolated del(20q), which corresponded in size to the clone of undifferentiated cells and to the clone with pathogenic variants detected by NGS in the BCOR, RUNX1, and SRSF2 genes. Myeloma therapy decreased both MM and undifferentiated cells; however, within four months, pDC-AML evolved with del(20q) and higher variant allele frequencies of the previously detected gene variants. Remission was achieved with standard AML chemotherapy. Conclusions: This case supports evidence that MM-associated immune dysfunction and bone marrow niche alterations may promote secondary myeloid malignancies independently of cytotoxic therapy. It demonstrates the earliest events in pDC-AML evolution. Furthermore, the immature immunophenotype raises the question of appropriate treatment, since a diagnosis of acute undifferentiated leukemia can be established.
Ključne besede:dendritic cells, multiple myeloma, acute undifferentiated leukemia
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2026
Št. strani:str. 1-8
Številčenje:Vol. 18, issue 1, [article no.] 3
PID:20.500.12556/DiRROS-24952 Novo okno
UDK:616
ISSN pri članku:2038-8330
DOI:10.3390/hematolrep18010003 Novo okno
COBISS.SI-ID:263433475 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 5. 1. 2026;
Datum objave v DiRROS:05.01.2026
Število ogledov:218
Število prenosov:98
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Hematology reports
Skrajšan naslov:Hematol. report.
Založnik:PagePress Publications
ISSN:2038-8330
COBISS.SI-ID:4197695 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0289-2019
Naslov:Značilnosti malignih neoplazem, pomembne za diagnozo ter napoved poteka bolezni in izida zdravljenja

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20230070
Naslov:Uskladitev izvajanja specialnih hematoloških preiskav z zahtevami evropske direktive IVDR

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj